research use only

Atomoxetine HCl 5-HT Receptor inhibitor

Cat.No.S3175

Atomoxetine (LY 139603) is a selective norepinephrine (NE) transporter inhibitor with Ki of 5 nM, with 15- and 290-fold lower affinity for human 5-HT and DA transporters.
Jump to

Quality Control

Batch: S317501 DMSO]58 mg/mL]false]Ethanol]37 mg/mL]false]Water]2 mg/mL]false Purity: 99.96%
99.96

Solubility

In vitro
Batch:

DMSO : 58 mg/mL (198.75 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 37 mg/mL

Water : 2 mg/mL

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 291.82 Formula

C17H21NO.HCl

Storage (From the date of receipt)
CAS No. 82248-59-7 Download SDF Storage of Stock Solutions

Synonyms LY 139603 HCl SMILES CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2.Cl

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
Norepinephrine (NE) transporter
5 nM(Ki)
5-HT
77 nM(Ki)
DA transporter
1451 nM(Ki)
In vitro
Atomoxetine is a selective norepinephrine reuptake inhibitor with Ki of 5 nM, compared with 77 and 1451 nM for binding to serotonin and dopamine transporters.
In vivo
In microdialysis studies, atomoxetine increases extracellular (EX) levels of NE in prefrontal cortex (PFC) 3-fold, but does not alter 5-HTEX levels. Atomoxetine also increases DAEX concentrations in PFC 3-fold, but does not alter DAEX in striatum or nucleus accumbens. Atomoxetine increases Fos by 3.7-fold in PFC, but not in the striatum or nucleus accumbens. Atomoxetine selectively inhibits the presynaptic uptake of norepinephrine in adrenergic neurons in animals, and has activity in animal models of depression.
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-07-23)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07724132 RECRUITING
Alzheimer's Disease (AD); Mild Cognitive Impairment Due to Alzheimer's Disease; Alzheimer Disease Dementia
University College, London
2026-07-24 PHASE3
NCT04216186 RECRUITING
ADHD
Sherief Abd-Elsalam
2018-11-01 PHASE3
NCT07679282 NOT_YET_RECRUITING
Obstructive Sleep Apnea (OSA)
Sairam Parthasarathy
2026-09-01 PHASE4
NCT00262470 ACTIVE_NOT_RECRUITING
Tachycardia; Chronic Orthostatic Intolerance
Satish R. Raj
1997-04 PHASE1; PHASE2
NCT06573970 RECRUITING
Posttraumatic Stress Disorder With Attention Defic
VA Office of Research and Development
2026-04-01 PHASE4
NCT06899178 RECRUITING
Melanocortin Obesity Syndrome; MCOS
Icahn School of Medicine at Mount Sinai
2026-09-01 PHASE2

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map